Yes, a single willow bark BHA toner formula can be sold in both the US and EU, but the label, claims, and compliance documentation must be adapted for each market — the formula itself typically does not need to change, provided the cosmetic chemist designed it with both regulatory frameworks in mind from the start.
In the United States, a willow bark BHA toner is regulated as a cosmetic under the FD&C Act as long as it makes only cosmetic claims ("exfoliating," "clarifying," "brightening pores"). The FDA requires accurate INCI labeling, net quantity declaration, manufacturer/distributor name and address, and appropriate warning statements. No premarket registration is required for cosmetics under current law (though the Modernization of Cosmetics Regulation Act of 2022 introduced new facility registration and product listing requirements phasing in through 2024–2025 — confirm current deadlines with your compliance counsel).
In the EU, the same formula must comply with EU Cosmetics Regulation (EC) No. 1223/2009. Key differences from US requirements include: a mandatory Cosmetic Product Safety Report signed by a qualified safety assessor; a Product Information File kept accessible in the EU; a designated Responsible Person established in the EU (or UK for Great Britain); and INCI labeling in compliance with EU-specific ingredient name conventions. The EU's salicylate limits (0.5% effective salicylate in leave-on products) must be confirmed by your cosmetic chemist. Willow bark extract at typical inclusion rates (1%–3% of a 5:1–10:1 standardized extract) usually falls within this limit, but the calculation must be documented.
Presentation differences: EU labels require the "period after opening" symbol (the open-jar icon with a number of months), the nominal quantity in metric units, and a "Made in" country of origin if manufactured outside the EU. US labels require net weight in both metric and US customary units. You will almost certainly need market-specific label artwork even if the formula is identical.
Claims are where the biggest divergence occurs. Language like "reduces acne" or "treats blemishes" triggers drug status in the US and may require substantiation under EU claims regulations. Stick to function-based cosmetic claims in both markets and document your claim substantiation file.
The practical implication: commission your cosmetic chemist to calculate salicylate equivalents from your willow bark extract batch from day one, design the formula to land below EU leave-on limits, and avoid OTC drug language in all markets. That single formula can then serve both markets with only documentation and label changes — no reformulation required.
Read the full guide on Private Label Willow Bark BHA Toner Manufacturer Low MOQ →